Peptidomimetics for the treatment of norovirus infection
The present invention is directed to compounds, compositions and methods for preventing, treating or curing Norovirus infection in human subjects or other animal hosts.
1. A compound of the following formula:
or a pharmaceutically acceptable salt thereof, wherein:
R 5 is selected from
R 2 , R 2 ′, R 10 , R 10 ′, R 11 and R 11 ′ are, independently, hydrogen, CF 3 , C 1-6 alkyl, C 1-6 haloalkyl, or C 2-6 alkenyl,
R 12 , R 12 ′ are, independently, C 1-6 alkyl, C 1-6 haloalkyl, or C 2-6 alkenyl,
R 12 and R 12 can come together to form an optionally substituted C 3-7 ring, optionally containing an N, O, or S;
R 8 is, independently, optionally substituted C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, aryl, or arylalkyl;
m, n, p and r are independently 0, 1, 2, 3, 4 or 5;
q is 1, 2, 3, 4 or 5,
X is a bond,
Y is independently CI, F, I or Br,
R 12 is hydrogen, CF 3 , CO 2 R′, S(O) 2 R′, S(O) 2 N(R′) 2 , P(O)(OR′) 2 , C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 alkoxyalkyl, C 1-6 alkyl, arylalkoxycarbonyl, C 1-6 haloalkyl, heterocyclylalkyl, or C 1-6 hydroxy alkyl;
R 6 and R 6′ are, independently, hydrogen, halogen, CF 3 , hydroxy, N(R′)S(O) 2 R′, S(O) 2 R′, S(O) 2 N(R′) 2 , C 1-6 alkoxy, C 2-6 alkenyl, cyano, C 2-6 alkynyl, C 3-6 alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, C 1-6 alkyl, arylalkoxycarbonyl, carboxy, C 1-6 haloalkyl, heterocyclylalkyl, or C 1-6 hydroxyalkyl,
or R 6 and R 6′ , together with the carbon to which they are attached, form a carbonyl;
each R′ is, independently, H, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, aryl, heteroaryl, alkylaryl, or arylalkyl,
the R′ groups, and other optionally substituted groups, can optionally be substituted with one or more substituents, which substituents are, independently, halo, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, alkoxyalkyl, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrazine, carbamate, phosphonic acid, or phosphonate;
two R′ residing on the same carbon or nitrogen atom can come together to form a C 3-6 ring optionally containing an N, O, or S;
R 6 and R 6 can come together to form an optionally substituted double bond, a C 3-6 ring optionally containing an N, O, or S;
R 7 and R 7′ are, independently, hydrogen, CF 3 , N(R′)S(O) 2 R′, S(O) 2 R′, S(O) 2 N(R′) 2 , C 1-6 alkoxy, C 2-6 alkenyl, cyano, C 2-6 alkynyl, C 3-6 alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, C 1-6 alkyl, arylalkoxycarbonyl, carboxy, C 1-6 haloalkyl, heterocyclylalkyl, or C 1-6 hydroxyalkyl;
R 7 and R 7′ can come together to form an optionally substituted double bond or a C 3-6 ring optionally containing an N, O, or S;
R 4 and R 3 are, independently, optionally substituted C 1-6 alkyl, C 1-6 haloalkyl, C 2-8 alkoxyalkyl, arylalkyl, heteroarylalkyl, or —CH 2 —R 4′ ,
R 4′ is a six-membered ring or a six-membered bridged or spiro-fused ring containing zero, one, or two heteroatoms, which are independently N, O, or S, a seven-membered bridged or spiro-fused ring containing zero, one, or two heteroatoms, which are, independently, N, O, or S, a five-membered ring containing zero, one, or two heteroatoms, which are, independently, N, O, or S; a four-membered ring containing zero, one, or two heteroatoms, which are, independently, N, O, or S, or a three membered ring; and
R 1 is optionally substituted aryl, heteroaryl, aryloxy, heteroaryloxy, arylalkoxy, or heteroarylalkoxy.
2. A compound of the following formula:
or a pharmaceutically acceptable salt thereof, wherein:
R 5 is
ketoamides, bisulfite salts,
or
R 9 is, independently, optionally substituted C 1-6 alkyl, C 1-6 haloalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl,
R 4 and R 3 are, independently, optionally substituted C 1-6 alkyl, C 1-6 haloalkyl, C 2 -8 alkoxyalkyl, arylalkyl, heteroarylalkyl, or —CH 2 —R 4′ ,
R 4′ is a six-membered ring or a six-membered bridged or spiro-fused ring containing zero, one, or two heteroatoms, which are independently N, O, or S, a seven-membered bridged or spiro-fused ring containing zero, one, or two heteroatoms, which are, independently, N, O, or S, a five-membered ring containing zero, one, or two heteroatoms, which are, independently, N, O, or S; a four-membered ring containing zero, one, or two heteroatoms, which are, independently, N, O, or S, or a three membered ring;
R 1 is optionally substituted aryl, heteroaryl, aryloxy, heteroaryloxy, arylalkoxy, or heteroarlalkoxy,
R 2 , R 2′ , R 10 and R 10 ′ are, independently, hydrogen, CF 3 , C 1-6 alkyl, C 1-6 haloalkyl, or C 2-6 alkenyl,
X is, independently, a bond, O or NH,
m, n, and p are, independently, 0, 1, 2, 3, 4 or 5;
when n and m are not 1;
R 6 and R 6′ are, independently, hydrogen, halogen, CF 3 , hydroxy, N(R′)S(O) 2 R′, S(O) 2 R′, S(O) 2 N(R′) 2 , C 1-6 alkoxy, C 2-6 alkenyl, cyano, C 2-6 alkynyl, C 3-6 alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, C 1-6 alkyl, arylalkoxycarbonyl, carboxy, C 1-6 haloalkyl, heterocyclylalkyl, or C 1-6 hydroxyalkyl; or R 6 and R 6 ′, together with the carbon to which they are attached, form a carbonyl,
each R′ is, independently, H, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, aryl, heteroaryl, alkylaryl, or arylalkyl,
the R′ groups can optionally be substituted with one or more substituents, which substituents are, independently, halo, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, alkoxyalkyl, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrazine, carbamate, phosphonic acid, or phosphonate;
two R′ residing on the same carbon or nitrogen atom can come together to form a C 3-6 ring optionally containing a N, O, or S heteroatom;
R 6 and R 6′ can come together to form an optionally substituted double bond or a C 3-6 ring optionally containing a N, O, or S heteroatom;
R 7 and R 7′ are, independently, hydrogen, CF 3 , N(R′)S(O) 2 R′, S(O) 2 R′, S(O) 2 N(R′) 2 , C 1-6 alkoxy, C 2-6 alkenyl, cyano, C 2-6 alkynyl, C 3-6 alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, C 1-6 alkyl, arylalkoxycarbonyl, carboxy, C 1-6 haloalkyl, heterocyclylalkyl, or C 1-6 hydroxy alkyl;
R 7 and R 7′ can come together to form an optionally substituted double bond or a C 3 -6 ring optionally containing a N, O, or S heteroatom; and
when n and m are 1, at least one or R 2 , R 6 , R 6′ , R 7 and R 7′ is not hydrogen.
3. A compound of the following formula:
or a pharmaceutically acceptable salt or prodrug thereof, wherein:
R 5 is
ketoamides, bisulfite salts,
R 9 is, independently, optionally substituted C 1-6 , alkyl, C 1-6 haloalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl,
R 2 and R 2 ′ are, independently, hydrogen, CF 3 , C 1-6 alkyl, C 1-6 haloalkyl, or C 2-6 alkenyl,
R 3 is, independently, optionally substituted C 1-6 alkyl, C 1-6 haloalkyl, C 2-8 alkoxyalkyl, arylalkyl, heteroarylalkyl, or —CH 2 —R 4′ ,
R 4 is, independently, optionally substituted C 1-6 haloalkyl, C 2-8 alkoxyalkyl, heteroarylalkyl, or CH 2 —R 4′ ,
R 4′ is a six-membered ring or a six-membered bridged or spiro-fused ring containing zero, one, or two heteroatoms, which are independently N, O, or S, a seven-membered bridged or spiro-fused ring containing zero, one, or two heteroatoms, which are, independently, N, O, or S, a five-membered ring containing zero, one, or two heteroatoms, which are, independently, N, O, or S; a four-membered ring containing zero, one, or two heteroatoms, which are, independently, N, O, or S, or a three membered ring;
R 1 is optionally substituted aryl, heteroaryl, aryloxy, heteroaryloxy, arylalkoxy, or heteroarlalkoxy,
p is 0, 1, 2, 3, 4 or 5; and
X is a bond, O or NH.
4. A compound of the following formula:
or a pharmaceutically acceptable salt thereof, wherein:
R 5 is
ketoamides, bisulfite salts,
wherein a ketoamide has the formula —C(O)C(O)NHR x , where R x is a branched or unbranched alkyl, cycloalkyl, or arylalkyl, and an a-hydroxyphosphonate of the formula —CH(O)(P═O)(OR y ) 2 , where each R y is H, a substituted or unsubstituted alkyl, aryl, or arylalkyl, and a bisulfite has the formula —H(OH)SO 3 − , and the salt is any pharmaceutically acceptable salt,
R 9 is, independently, optionally substituted C 1-6 alkyl, C 1-6 haloalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl,
R 4 is optionally substituted C 1-6 alkyl, cycloalkyl, aryl, arylakyl, alkenyl, alkynyl, or a natural amino acid side chain,
R 4′ is a six-membered ring or a six-membered bridged or spiro-fused ring containing zero, one, or two heteroatoms, which are independently N, O, or S, a seven-membered bridged or spiro-fused ring containing zero, one, or two heteroatoms, which are, independently, N, O, or S, a five-membered ring containing zero, one, or two heteroatoms, which are, independently, N, O, or S; a four-membered ring containing zero, one, or two heteroatoms, which are, independently, N, O, or S, or a three membered ring;
R 1 is optionally substituted aryl, heteroaryl, aryloxy, heteroaryloxy, arylalkoxy, or heteroarlalkoxy,
p is 0, 1, 2, 3, 4 or 5;
X is, independently, a bond, O or NH,
R 3 is, independently, optionally substituted C 1-6 haloalkyl, C 2-8 alkoxyalkyl, heteroarylalkyl, or —CH 2 —R 4′ , and
R 2 and R 2 ′ are, independently, hydrogen, CF 3 , C 1-6 alkyl, C 1-6 haloalkyl, or C 2-6 alkenyl.
5. A compound of the following formula:
or a pharmaceutically acceptable salt thereof, wherein:
R 5 is
ketoamides, bisulfite salts,
R 9 is, independently, optionally substituted C 1-6 alkyl, C 1-6 haloalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl,
R 4 is optionally substituted C 1-6 alkyl, cycloalkyl, aryl, arylakyl, alkenyl, alkynyl, or a natural amino acid side chain, R 4′ is a six-membered ring or a six-membered bridged or spiro-fused ring containing zero, one, or two heteroatoms, which are independently N, O, or S, a seven-membered bridged or spiro-fused ring containing zero, one, or two heteroatoms, which are, independently, N, O, or S, a five-membered ring containing zero, one, or two heteroatoms, which are, independently, N, O, or S; a four-membered ring containing zero, one, or two heteroatoms, which are, independently, N, O, or S, or a three membered ring;
R 1 is optionally substituted aryl, heteroaryl, aryloxy, heteroaryloxy, arylalkoxy, or heteroarlalkoxy,
p is 0, 1, 2, 3, 4 or 5;
X is, independently, a bond, O or NH,
R 3 is, independently, optionally substituted C 1-6 haloalkyl, C 2-8 alkoxyalkyl, heteroarylalkyl, or —CH 2 —R 4 ′, and
R 2 and R 2 ′ are, independently, CF 3 , C 1-6 alkyl, C 1-6 haloalkyl, or C 2-6 alkenyl.
6. A compound having the following formula:
or a pharmaceutically acceptable salt thereof,
wherein:
R 1 is optionally substituted aryl, heteroaryl, aryloxy, heteroaryloxy, arylalkoxy, or heteroarylalkoxy,
R 2 and R 2 ′ are, independently, H, —NH 2 , —H-carboxybenzyl, CF 3 , C 1-6 alkyl, C 1-6 haloalkyl, or C 2-6 alkenyl, where the —NH 2 can optionally be protected with an amine protecting group,
R 3 is, independently, optionally substituted C 1-6 haloalkyl, C 2-8 alkoxyalkyl, heteroarylalkyl, or —CH 2 —R 4 ′,
R 4 is optionally substituted C 1-6 alkyl, cycloalkyl, aryl, arylakyl, alkylaryl, alkenyl, alkynyl, or a natural amino acid side chain,
R 4′ is a six-membered ring or a six-membered bridged or spiro-fused ring containing zero, one, or two heteroatoms, which are independently N, O, or S, a seven-membered bridged or spiro-fused ring containing zero, one, or two heteroatoms, which are, independently, N, O, or S, a five-membered ring containing zero, one, or two heteroatoms, which are, independently, N, O, or S; a four-membered ring containing zero, one, or two heteroatoms, which are, independently, N, O, or S, or a three membered ring;
R 5 is an acrylamide (—C(R 2 )═C(R 2 )—, C 1-6 -haloalkyl, C 1-6 -alkyl sulfonate, aryl sulfonate, heteroaryl sulfonate, C 1-6 -alkyl sulfoxide, or C 1-6 -ketoalkyl, wherein the alkyl moiety on any of these groups can be substituted with an epoxide (on two adjacent carbons), CN, OH, halo, keto, or —CF 3 ,
R 6 and R 6′ are, independently, hydrogen, halogen, CF 3 , hydroxy, N(R′)S(O) 2 R′, S(O) 2 R′, S(O) 2 N(R′) 2 , C 1-6 alkoxy, C 2-6 alkenyl, cyano, C 2-6 alkynyl, C 3-6 alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, C 1-6 alkyl, arylalkoxycarbonyl, carboxy, C 1-6 haloalkyl, heterocyclylalkyl, or C 1-6 hydroxyalkyl, or R 6 and R 6 ′, together with the carbon to which they are attached, form a carbonyl;
R 6 and R 6′ can come together to form an optionally substituted double bond, a C 3-6 ring optionally containing an N, O, or S;
R 7 and R 7′ are, independently, hydrogen, CF 3 , N(R′)S(O) 2 R′, S(O) 2 R′, S(O) 2 N(R′) 2 , C 1-6 alkoxy, C 2-6 alkenyl, cyano, C 2-6 alkynyl, C 3-6 alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, C 1-6 alkyl, arylalkoxycarbonyl, carboxy, C 1-6 haloalkyl, heterocyclylalkyl, or C 1-6 hydroxy alkyl;
R 10 and R 10 ′ are, independently, hydrogen, CF 3 , C 1-6 alkyl, C 1-6 haloalkyl, or C 2-6 alkenyl,
m, n and p are independently 0, 1, 2, 3, 4 or 5; and
X is, independently, a bond, O or NH, and pharmaceutically-acceptable salts and prodrugs thereof.
7. A compound selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
8. The compound of claim 7 , wherein the compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
9. A compound selected from the group consisting of
and pharmaceutically-acceptable salts thereof.
10. A pharmaceutical composition comprising a compound of claim 1 , and a pharmaceutically-acceptable carrier.
11. The composition of claim 10 , wherein the composition is a transdermal composition or a nanoparticulate composition.
12. The pharmaceutical composition of claim 11 , further comprising a second antiviral agent.
13. The pharmaceutical composition of claim 12 , wherein the second antiviral agent is selected from the group consisting of a polymerase inhibitors, protease inhibitors, anti-emetics, anti-diarrheals, cellular deubiquitinase inhibitors, IFN-λ inhibitors, agents of distinct or unknown mechanism, and combinations thereof.
14. A method for treating a host infected with Norovirus, or reducing the biological activity of an infection with Norovirus in a host, comprising administering an effective amount of a compound of claim 1 to a patient in need of treatment thereof.
15. The method of claim 14 , wherein the method further comprising administering another Norovirus virus agent in combination or alternation with the compound of claim 1 .